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Psychological conditions, including stress, compromise immune defenses. Although this 
concept is not novel, the molecular mechanism behind it remains unclear. Neuropeptide Y 
(NPY) in the central nervous system is a major regulator of numerous physiological functions, 
including stress. Postganglionic sympathetic nerves innervating lymphoid organs release NPY, 
which together with other peptides activate five Y receptors (Y1, Y2, Y4, Y5, and y
 
6
 
). Using 
Y1-deficient (Y1
 
 
 
/
 
 
 
) mice, we showed that Y1
 
 
 
/
 
 
 
 T cells are hyperresponsive to activation 
and trigger severe colitis after transfer into lymphopenic mice. Thus, signaling through Y1 
receptor on T cells inhibits T cell activation and controls the magnitude of T cell responses. 
Paradoxically, Y1
 
 
 
/
 
 
 
 mice were resistant to T helper type 1 (Th1) cell–mediated inflammatory 
responses and showed reduced levels of the Th1 cell–promoting cytokine interleukin 12 and 
reduced interferon 
 
 
 
 production. This defect was due to functionally impaired antigen-
presenting cells (APCs), and consequently, Y1
 
 
 
/
 
 
 
 mice had reduced numbers of effector 
T cells. These results demonstrate a fundamental bimodal role for the Y1 receptor in the 
immune system, serving as a strong negative regulator on T cells as well as a key activator of 
APC function. Our findings uncover a sophisticated molecular mechanism regulating immune 
cell functions that can lead to stress-induced immunosuppression.
 
Psychological conditions, such as stress or de-
pression,  are known to compromise immune
defenses and increase the likelihood of infec-
tions, autoimmunity, or cancer (1). Although
this concept has been well accepted for decades,
the molecular mechanisms controlling this inter-
play remain unclear. Neuropeptides, neurotrans-
mitters, hormones, and cytokines are thought to
participate in the modulation of immune func-
tions by the central or peripheral nervous system
(1). Studies looking at the effect of a defective
sympathetic nervous system on immune func-
tions and autoimmunity have focused on cate-
cholamines as they are viewed as the major
sympathetic transmitters (2). Although cate-
cholamines have some effects on immune func-
tions and can modulate clinical manifestations in
some animal models of autoimmune diseases (3),
their function does not explain other major im-
mune effects associated with altered sympathetic
nervous system functions.
Postganglionic sympathetic nerves that inner-
vate primary and secondary lymphoid organs also
release neuropeptide Y (NPY; reference 4). Five
Y receptors (Y1, Y2, Y4, Y5, and y
 
6
 
) are
known to mediate the actions of NPY together
with two other family members, peptide YY
and pancreatic polypeptide (5). NPY is widely
expressed in the central and peripheral nervous
system and is a major regulator for many im-
portant physiological functions, including the
regulation of food consumption and energy
homeostasis (6). In addition, NPY controls many
behavioral aspects, such as anxiety and other
depression-related disorders (7), and recent
findings point to a role for this neuropeptide in
immune functions (3, 8). NPY appears to be
particularly important in modulating cytokine
release from leukocytes and affecting Th1 T
cell function (8).
The polarization of T cell responses to Th1
or Th2 cells is central for T cell effector responses
and also has relevance for the development of
autoimmune and allergic diseases (9). Th1 T
cells secrete IFN-
 
 
 
, whereas Th2 T cells pro-
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duce predominantly IL-4 and IL-5 (9). Th1 T cells specifi-
cally contribute to the progression of several inflammatory
and autoimmune disorders, such as delayed-type hypersensi-
tivity (DTH), colitis, rheumatoid arthritis, and multiple scle-
rosis (10). In contrast, Th2 T cells participate in allergic reac-
tions such as asthma (11). Activation of APCs is a critical
event for determining the polarization of T cell responses,
and production of IL-12 by DCs, for instance, is required for
Th1 T cell differentiation (12). A recent study showed that
treatment of mice with NPY suppressed experimental au-
toimmune encephalomyelitis (EAE), a model of Th1 cell–
driven autoimmune disease in mice (13). Using agonist and
antagonist reagents, this study showed that this effect was
triggered through the Y1 receptor expressed on T cells, sug-
gesting that the NPY–Y1 axis represses Th1 T cell effector
functions (13). Yet, opposite results were obtained in a Th1
cell–mediated experimental model of colitis in mice (14). In
this model, Y1
 
 
 
/
 
 
 
 mice, or normal mice treated with a Y1
receptor antagonist, were protected against colitis compared
with control animals, suggesting that signaling through the
Y1 receptor contributed to disease progression (14). There-
fore, the major challenge in this system is to explain how sig-
nals through Y1 receptors on T cells can inhibit their activa-
tion and protect mice in a Th1 cell–mediated EAE model
while lack or inhibition of Y1 signaling protects mice against
Th1 cell–mediated colitis.
In recent years, various Y receptor–deficient mice have
been generated, and these have proved invaluable for dis-
secting the physiological roles of this complicated receptor–
ligand system (6). Here, using Y1
 
 
 
/
 
 
 
 mice, we show that
Y1
 
 
 
/
 
 
 
 T cells were hyperresponsive to activation and trigger
severe colitis after transfer into lymphopenic mice. Paradoxi-
cally, Y1
 
 
 
/
 
 
 
 mice were resistant to Th1 cell–mediated in-
flammatory responses, which was due to a functional defect
in Y1
 
 
 
/
 
 
 
 APCs that masked the hyperreactivity of Y1
 
 
 
/
 
 
 
 T
cells. Thus, Y1 signaling serves a bimodal role in the im-
mune system as an activator of APC function and a repressor
of T cell activation.
 
RESULTS
Altered lymphocyte numbers in the spleen and LNs 
of Y1
 
 
 
/
 
  
 
mice
 
To ascertain the precise functional role and mechanisms for
NPY in the immune system, we assessed mice deficient
in various NPY receptors and noted significantly reduced
spleen sizes in Y1
 
 
 
/
 
 
 
 mice (Fig. 1 A), but not in Y2
 
 
 
/
 
 
 
 and
Y4
 
 
 
/
 
 
 
 mice (not depicted). Smaller Y1
 
 
 
/
 
 
 
 spleen sizes cor-
related with reduced B cell numbers as assessed by FACS
analysis of anti-B220–stained splenocytes (Fig. 1 B). Spleno-
cytes were also stained with antibodies to IgM, CD23,
CD21, and CD24, and B cell subsets were gated by FACS as
described previously (15). Absolute numbers of cells in all B
cell subsets were reduced, including immature transitional
type 1 and 2 B cells and marginal zone B cells, but particu-
larly mature B cells (Fig. 1 C). B cell numbers were also re-
duced in LNs (not depicted). Numbers of CD8
 
 
 
 T cells
were also slightly reduced in the spleen (Fig. 1 D), whereas
numbers of splenic CD4
 
 
 
 T cells were normal (not de-
picted). Interestingly, a profound alteration of the T cell
compartment was seen in peripheral LNs with significantly
Figure 1. Altered T and B cell numbers in Y1 /  mice and Y1 
expression in immune cells. (A) Spleen weight of Y1 /  and Y1 /  mice. 
(B) Absolute numbers of B220  B cells in the spleen of Y1 /  and Y1 /  mice. 
(C) Absolute numbers of splenic B cell subsets (immature transitional type 1 
[T1], type 2 [T2] mature, and marginal zone [MZ] B cells) in Y1 /  (white bars) 
and Y1 /  mice (black bars) as indicated. (D) Absolute numbers of CD8  T 
cells in the spleen of Y1 /  and Y1 /  mice. (E) Representative FACS plots 
illustrate the increased proportions of naive T cells (top left quadrant) and 
decreased numbers of effector T cells (bottom right quadrant) in peripheral 
LNs of Y1 /  mice compared with Y1 /  mice (percent shown in each 
quadrant). Absolute numbers of naive T cells (F) and effector memory T cells 
(G) in the peripheral LNs of Y1 /  mice (black bars) and Y1 /  (white bars). 
Cells were stained and analyzed as described previously (reference 15). 
(E) RT-PCR for murine Y1 using cDNA from tissues, sorted immune cells, and 
control DNA as indicated. High expression in the spleen, mast cells, NK cells, 
and DCs, and B cells and reduced expression in CD4 and CD8 T cells as well as 
macrophages. A Y1 cDNA construct was used as a positive control and cDNA 
prepared from Y1 /  macrophages was used as a negative control. Mean   
SD of eight animals are shown in A–D, F, and G. ***, P   0.001; **, P   0.005; 
and *, P   0.05 as determined by t test (ANOVA). 
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increased numbers of naive CD4
 
 
 
 and CD8
 
 
 
 T cells (Fig. 1,
E and F) and decreased numbers of effector T cells (Fig. 1, E
and G) when compared with Y1
 
 
 
/
 
 
 
 mice. This phenome-
non was clearly apparent from the greatly increased propor-
tion of naive CD44
 
lo 
 
L-selectin
 
hi
 
 CD4
 
 
 
 or CD8
 
 
 
 T cells on
representative dot plot histograms (Fig. 1 E, top left quadrant
of dot plots). T cell development in the thymus was normal
(not depicted).
We prepared RNA from normal splenocytes and cell-
sorted immune cell subsets and assessed expression of the Y1
receptor in these samples using quantitative real-time PCR.
We detected high levels of Y1 expression in the spleen, DCs,
NK cells, and mast cells, and lower levels in T cells, B cells,
and macrophages (Fig. 1 H). Expression of other Y receptors
was unaffected in the same cells/tissue isolated from Y1
 
 
 
/
 
 
 
mice (not depicted). In sum, Y1 deficiency leads to signifi-
cant alterations of the lymphocyte compartments, and the rel-
atively widespread expression of Y1 receptor in immune cells
suggests an important role for Y1 in immune functions.
 
Impaired production of IgG2a in Y1
 
 
 
/
 
 
 
 
 
mice
 
Reduced B cell numbers in Y1
 
 
 
/
 
 
 
 mice prompted us to
measure by ELISA total serum Ig levels in Y1
 
 
 
/
 
 
 
 mice. A
specific and significant reduction of total IgG2a levels was ob-
served in resting Y1
 
 
 
/
 
 
 
 mice compared with Y1
 
 
 
/
 
 
 
 mice
(Fig. 2 A). Immunization of Y1
 
 
 
/
 
 
 
 mice with the T-inde-
pendent antigen nitrophenyl (NP)-Ficoll or the T-dependent
antigen NP-OVA to elicit primary and secondary responses
revealed defective antigen-specific IgG2a responses (Fig. 2,
B–D). Although secondary responses to NP-OVA in Y1
 
 
 
/
 
 
 
mice led to a higher NP-specific IgG2a response compared
with a primary response in these mice, the secondary NP-
specific IgG2a response in Y1
 
 
 
/
 
 
 
 mice still remained signifi-
cantly inferior to that of Y1
 
 
 
/
 
 
 
 mice (Fig. 2 D). In contrast to
the IgG2a response, the IgG2b, IgM, and IgA response to
NP-Ficoll was higher in Y1
 
 
 
/
 
 
 
 mice compared with Y1
 
 
 
/
 
 
 
mice (Fig. 2 B). Interestingly, despite a 50% reduction in ma-
ture B cell numbers (Fig. 1 B), antigen-specific IgG1 se-
cretion was not affected, suggesting possible compensatory
mechanisms for some aspects of the antibody production
(Fig. 2). Thus, Y1
 
 
 
/
 
 
 
 mice display a general defect in IgG2a
production, which was not corrected upon immunization.
 
Impaired Th1 cell–mediated DTH and dextran-sulfate 
sodium (DSS)-induced colitis in Y1
 
 
 
/
 
 
 
 
 
mice
 
Ig class switching to the IgG2a isotype requires Th1 cell cy-
tokines, particularly IFN-
 
 
 
, and is viewed as a hallmark of a
Th1 cell response (16). The consistent, general, and selective
reduction of IgG2a levels in Y1
 
 
 
/
 
 
 
 mice led us to infer that
Y1 expression might be important for Th1 cell responses.
Therefore, we tested the response of Y1
 
 
 
/
 
 
 
 mice to meth-
ylated BSA (mBSA), which is used to elicit a classic DTH
response that is Th1 cell–mediated (17). Swelling in Y1
 
 
 
/
 
 
 
mice was significantly reduced to 55% of the average re-
sponse seen in Y1
 
 
 
/
 
 
 
 mice 24 h after challenge with mBSA
(Fig. 3, A and B). Levels of mBSA-specific IgG2a were also
reduced in Y1
 
 
 
/
 
 
 
 mice (not depicted). When lymphocytes
were prepared from the draining inguinal LNs of these mice
and restimulated with mBSA in vitro, the proliferation of
Y1
 
 
 
/
 
 
 
 LN cells and the production of IFN-
 
 
 
 was reduced
compared with that of control cells (Fig. 3, C and D, respec-
tively). In contrast, IL-4 levels were unchanged (Fig. 3 D),
suggesting that Y1 receptor signaling was essential for opti-
mal Th1 T cell responses, but Y1 deficiency did not skew
the T cell response toward a Th2 T cell response.
To verify whether this phenomenon could be repro-
duced in a mucosal Th1 cell disease model, we fed Y1
 
 
 
/
 
 
 
and Y1
 
 
 
/
 
 
 
 mice with DSS, an irritant that induces colitis
by destroying the intestinal lining (18). Under these condi-
Figure 2. Impaired IgG2a production in Y1 /  mice. (A) Total serum 
Ig levels in Y1 /  and Y1 /  mice. (B) NP-specific antibody titers 7 d after 
immunization with NP-Ficoll. (C) NP-specific antibody titers 7 d after 
NP-OVA immunization and (D) 14 d after a secondary immunization with 
NP-OVA. Mean and SD for six animals per group are shown in B–D, and 
eight animals are shown in A. IgG1, IgG2a, IgG2b, IgG3, IgM, and IgA 
levels, total or antigen-specific, are shown in Y1 /  (white bars) and Y1 /  
(black bars) mice. p-values as in Fig. 1.THE IMMUNOLOGICAL ROLE OF NEUROPEPTIDE Y1 RECEPTOR | Wheway et al. 1530
tions, our Y1 /  mice were protected against Th1 cell–medi-
ated DSS-induced colitis (not depicted). The specific benefit
from Y1 deficiency in DSS-mediated colitis was associated
with strongly reduced IFN-  serum levels (Fig. 3 E). These
results demonstrate that Y1 deficiency protects against Th1
cell–mediated inflammatory disorders via suppression of T
cell activation and reduction of IFN-  production. There-
fore, signaling through the Y1 receptor is essential for opti-
mal Th1 cell immune responses.
Y1 /  T cells are hyperresponsive to activation
Th1 cell responses are complex and involve several cell types
as well as the production of various factors (10). APCs, such
as DCs and macrophages, that produce IL-12 are the key el-
ements that drive the differentiation of activated T cells into
Th1 effector T cells (12). Studies using a mouse Th1 cell–
mediated model of EAE suggested that Y1 reduced EAE
symptoms and triggered repressive signals in T cells that in-
hibited T cell activation (13). Similarly, when we treated
normal mice with NPY this also prevented mBSA-mediated
DTH responses (not depicted). To explain these seemingly
conflicting results, we hypothesized that signaling through
Y1 may indeed trigger inhibitory signals in T cells but may
also be essential for the activation of APCs. Defective Y1 / 
APC functions would prevent T cell activation and Th1
cell–mediated disease in Y1 /  mice, whereas the adminis-
tration of NPY or Y1 agonists in a normal mouse would
trigger inhibitory signals in T cells, suppressing their activa-
tion and polarization into Th1 T cells in vivo. To test this
hypothesis, we analyzed the activation of Y1 /  T cells and
Y1 /  APCs separately.
First, we checked the function of cell-sorted Y1 /  T
cells in various in vitro and in vivo models for T cell activa-
tion. Interestingly, Y1 /  T cells were hyperresponsive to
stimulation with anti-CD3 or anti-CD3  anti-CD28 com-
pared with Y1 /  T cells (Fig. 4 A). A dose-response analy-
sis of Y1 /  and Y1 /  T cell responses to anti-CD3 stimu-
lation confirmed the increased sensitivity of Y1 /  T cells to
low-dose anti-CD3 stimulation (Fig. S1 A, available at http://
www.jem.org/cgi/content/full/jem.20051971/DC1), and
this correlated with a faster rate of cell division as assessed by
carboxyfluorescein diacetate succinimidyl ester (CFSE) stain-
ing (Fig. S1 B). Production of IL-2 and expression of the ac-
tivation marker CD69 were normal in Y1 /  T cells (Fig.
S1, C and D, respectively). Similarly, Y1 /  T cells were
much better responders in MLR compared with Y1 /  T
cells when inactivated Y1 /  splenocytes were used as stim-
ulators (Fig. 4 B). Conversely, the addition of increasing
amounts of NPY to an MLR using Y1 /  T cells as re-
sponders inhibited proliferation triggered by inactivated
Y1 /  stimulators (Fig. 4 C). Thus, Y1 signaling negatively
regulates T cell activation. Moreover, Y1 /  T cells are not
intrinsically defective but are in fact hyperresponsive to acti-
vation in vitro.
To confirm this result in vivo, we used a colitis model in
RAG1 /  mice induced by the transfer of cell-sorted naive
CD45RBhi CD4  T cells as described previously (19–21).
This model provides for a host with Y1 /  APCs into which
Y1 /  or Y1 /  CD4  CD45RBhi CD4  naive T cells are
transferred. If Y1 /  T cells are not defective, as our in vitro
assessment would suggest (Fig. 4, A and B), there should be
the usual development of colitis after the transfer of Y1 / 
CD4  CD45RBhi CD4  T cells into RAG1 /  mice. In-
deed, such a transfer did induce colitis, but it was of a more
rapid and severe type as soon as 10 d after transfer (Fig. 4 D).
In fact, mice receiving Y1 /  T cells were killed around day
15 due to disease severity and excessive weight loss associated
with this disease (Fig. 4 D), whereas RAG1 /  mice that re-
ceived Y1 /  T cells retained normal weight at day 15 (Fig. 4
Figure 3. Impaired Th1 cell inflammatory responses in Y1 /  mice. 
(A) Footpad swelling in Y1 /  and Y1 /  mice 24 h after secondary 
challenge with mBSA (n   10 per group). Mean values are represented by 
black bars. (B) Pictures of an inflamed paw of Y1 /  (top) and a protected 
paw from a Y1 /  mouse representative of A. (C) Proliferation of Y1 /  LN 
cells after a 72-h mBSA restimulation ex vivo. Four mice were analyzed 
and data is representative of two independent experiments. (D) IFN-  and 
IL-4 levels in the medium from cultures of ex vivo mBSA-restimulated LN 
cells (stimulated for 72 h). Each symbol represents an individual animal: 
squares, Y1 / ; diamonds, Y1 / . Average of triplicates are shown in D 
for each animal (n   7). (E) Serum levels of IFN-  in Y1 /  mice 7 d after 
inducing DSS-triggered colitis (eight animals analyzed per group). p-values 
as in Fig. 1.JEM VOL. 202, December 5, 2005 1531
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D) and were typically killed between day 21 and 28 (Fig. 4
D). Weight loss in these animals correlated with severe in-
flammation of the colon as shown by histopathologic analysis
(Fig. 4 E). At day 12, the colon of RAG1 /  mice that re-
ceived Y1 /  T cells showed a massive infiltration of leuko-
cytes in the lamina propria and, occasionally, in the submu-
cosa, prominent epithelial hyperplasia, and loss of mucin-
containing vesicles in the goblet cells (Fig. 4 E). In contrast,
RAG1 /  mice that received Y1 /  T cells and were killed
on the same day (day 12) showed little if any inflammation
(Fig. 4 E). Severe colonic inflammation in these mice was
only evident when the animals were killed on day 28 (Fig. 4
E). The exacerbated colitis that occurred after the transfer of
Y1 /  naive CD4  T cells into RAG1 /  mice was accom-
panied by a massive expansion of the splenic CD4  T cell
population (Fig. 4 F) and very high serum levels of IFN- 
(Fig. 4 G). Thus, Y1 /  T cells are functional in vivo, and
signaling through Y1 receptors in T cells is an essential regu-
latory feature that prevents T cell hyperactivity. Moreover,
Y1 /  T cells were able to differentiate to Th1 effector T
cells and produce IFN-  in this model as well as after activa-
tion with IL-12 plus anti–IL-4 in vitro (not depicted). There-
fore, reduced Th1 T cell responses, such as DTH (Fig. 3) or
DSS-induced colitis observed in Y1 /  mice (Fig. 3; refer-
ence 14), might be attributable to a defect in APC function,
but not to an intrinsic defect of Y1 /  T cells.
Impaired macrophage function in Y1 /  mice
To test for a possible defect in Y1 /  APC function, we first
tested inactivated Y1 /  splenocytes as stimulators with
Y1 /  T cells as responders in an MLR, and, as suspected,
the response was significantly reduced, indicating that anti-
gen presentation by Y1-deficient APCs is impaired (Fig. 5
A). To understand the nature of the defect in Y1 /  APCs,
we first measured by ELISA serum levels of IL-12, a key
cytokine driving the differentiation of activated CD4  T
cells into Th1 effector cells. IL-12 is produced primarily by
APCs, such as macrophages and DCs (12). IL-12 levels were
significantly lower in the serum of Y1 /  compared with
Y1 /  mice (Fig. 5 B). Mouse macrophages were isolated
from peritoneal lavage and activated with LPS to trigger cy-
tokine production, and the secretion of IL-12 and TNF into
the culture medium was measured by ELISA. Peritoneal
Y1 /  macrophages produced reduced amounts of IL-12
and TNF in response to LPS (Fig. 5, C and D, respectively).
As LPS activates Toll-like receptors (TLRs), particularly
TLR4, we checked whether activation through other TLRs
was also affected in Y1 /  mice. Peritoneal macrophages
Figure 4. Y1-deficient T cells are hyperresponsive in vitro and in 
vivo. (A) Proliferation of Y1 /  and Y1 /  T cells 72 h after stimulation 
with anti-CD3 or anti-CD3 plus anti-CD28 as indicated. (B) T cell proliferation 
in an MLR with Y1 /  APCs as stimulators. (C) Dose-dependent inhibitory 
effect of NPY on an MLR with Y /  responder and stimulator cells. Mean 
counts   SE of triplicates are shown, representative of five experiments in 
A–C. (D) Naive Y1 /  T cell induction of early onset of weight loss and 
colitis after transfer to RAG1 /  mice. Y1 /  donor T cells, white diamonds; 
Y1 /  donor T cells, black circles. (E) Histological analysis of hematoxylin 
and eosin–stained colon sections of RAG1 /  mice 12 (top) and 28 d 
(bottom) after the transfer of Y1 /  T cells and 12 d after the transfer of 
Y1 /  T cells (middle). Two representative mice shown out of eight mice 
analyzed. Magnification,  100. (F) Absolute numbers of splenic Y1 /  and 
Y1 /  CD4  T cells 15 d after transfer to RAG1 /  mice. (G) Serum levels 
of IFN-  in RAG /  mice 15 d after receiving Y1 /  or Y1 /  naive T cells 
as indicated. n   5 mice per group in D–F. p-values as in Fig. 1.THE IMMUNOLOGICAL ROLE OF NEUROPEPTIDE Y1 RECEPTOR | Wheway et al. 1532
were isolated and stimulated in culture with various TLR
ligands, such as LPS, R848, and peptidoglycan (PGN) spe-
cific for TLR4, TLR7/8, and TLR2, respectively. Y1 / 
macrophages produced significantly less TNF than Y1 / 
macrophages in response to stimulation through all these dif-
ferent TLRs (Fig. 5 D).
Both APCs and lymphocytes produce NPY after activa-
tion (22). Therefore, because the response of Y1 /  mac-
rophages was impaired ex vivo, NPY production by these
cells after activation might provide an autocrine signal via
the Y1 receptor necessary to tune APCs into effective acti-
vators of T cells. To test this hypothesis, we activated Y1 / 
macrophages with LPS in the presence or absence of a Y1-
specific antagonist peptide and measured the production of
TNF and IL-12 in the supernatants of these cultures by
ELISA. Inhibition of Y1 signaling after the addition of the
Y1 receptor antagonist led to reduced production of TNF
and IL-12 by normal LPS-activated peritoneal macrophages
(Fig. 5, E and F, respectively). These results suggest that
NPY produced by activated macrophages provides an auto-
crine signal through their Y1 receptor to promote an opti-
mal response and demonstrates that signaling through Y1 is
required for normal macrophage function.
Impaired DC function in Y1 /  mice
Mature DCs are very potent APCs driving T cell activation
and differentiation. We prepared BM-derived mouse DCs in
culture with GM-CSF and IL-4, and CD11c  cells were used
in activation assays. In contrast to the activation of Y1 / 
macrophages, the activation of BM-derived Y1 /  DCs with
LPS led to normal expression of activation markers (not de-
picted). However, uptake of an antigen, such as OVA-FITC,
by immature Y1 /  DCs was reduced compared with that of
Y1 /  immature DCs as determined by FACS analysis (Fig. 6,
A and B). The same result was obtained using FITC-dextran
(not depicted). We prepared BMDCs from Y1 /  or Y1 / 
mice and used these as immature cells, or cells activated with
LPS or anti-CD40 mAb. After inactivation, the stimulatory
activity of these purified DC preparations was tested in an
MLR using Y1 /  T cells as responders. The results showed
that activated Y1 /  DCs were poor stimulators compared
with activated Y1 /  DCs (Fig. 6 C). In addition, IL-12 pro-
duction by these DC preparations was also impaired (Fig. 6
D). Taken together, these results and those obtained with
macrophage preparations (Fig. 5) showed a marked impair-
ment of Y1 /  APC function, in particular IL-12 production,
consistent with defective Th1 cell responses in Y1 /  mice.
Next, we checked whether Y1 /  APC function was af-
fected in vivo. For this we used two strategies. First, we
crossed Y1 /  mice onto RAG1 / , generating double KO
mice. This model provides for a host with Y1 /  APCs in
which Y1 /  or hyperresponsive Y1 /  CD45RBhi CD4 
T cells can be injected to induce colitis as is shown in Fig.
4. We injected Y1 /  T cells (shown to be very potent
colitis inducers; Fig. 4) into RAG1 /    Y1 /  mice and
RAG1 /  control littermates. Fig. 6 E shows that injec-
Figure 5. Impaired macrophage function in Y1 /  mice. (A) Y1 /  T 
cell proliferation in an MLR with Y1 /  stimulators. Mean counts   SE of 
triplicates are shown, representative of three experiments. (B) Serum IL-12 
levels in Y1 /  (squares) and Y1 /  (diamonds) mice (n   15). (C) Production 
of IL-12 by Y1 /  (white squares) and Y1 /  (white diamonds) peritoneal 
macrophages after 4 h of stimulation with LPS. Seven Y1 /  and nine Y1 /  
mice were analyzed and the black bars indicate the mean levels. (D) TNF 
production by Y1 /  (white bars) and Y1 /  (black bars) peritoneal mac-
rophages after 4 h of LPS (100 and 500  g/ml), R848, and PGN stimulation. 
Five mice per group were analyzed. Production of TNF (E; left) or IL-12 
(F; right) by LPS-stimulated (for 4 h) Y1 /  peritoneal macrophages in the 
presence or absence of a Y1 peptide antagonist as indicated. Mean and SD 
of triplicates are shown. (D–F) are representative of three independent 
experiments. p-values as in Fig. 1.JEM VOL. 202, December 5, 2005 1533
ARTICLE
tion of Y1 /  T cells into RAG1 /  mice, but not into
RAG1 /    Y1 /  mice, induced colitis as soon as day 10 af-
ter T cell transfer, leading to weight loss of these animals com-
pared  with RAG1 /     Y1 /  mice that in fact gained
weight normally through the course of the experiment.
RAG1 /  mice, but not RAG1 /    Y1 /  mice, injected
with Y1 /  T cells developed diarrhea by day 15 and had to
be killed. This suggests that Y1 /  T cells failed to be acti-
vated in RAG1 /    Y1 /  mice due to a lack of Y1 ex-
pression on APCs and demonstrates that Y1 is critical for
proper APC function in vivo.
To further confirm the defect of Y1 /  APCs in vivo,
we set up a DC transfer system adapted from studies de-
scribed previously (23, 24). BM-derived Y1 /  and Y1 / 
DCs were prepared and pulsed with mBSA. These cells were
injected in two sets of Y1 /  mice. 1 wk later, mBSA was
injected in the footpad to trigger DTH. The results show
that the injection of mBSA-pulsed Y1 /  DCs was very effi-
cient at priming the recipient’s Y1 /  T cells, which led to a
robust DTH response (Fig. 6 F). This is in contrast to
mBSA-pulsed Y1 /  DCs, which showed impaired DTH
responses in Y1 /  mice (Fig. 6 F). Taken together, in vitro
and in vivo results show that Y1 /  APCs are defective and
fail to provide optimal stimulation to T cells.
Immune defects in Y1 /  mice are immune cell–specific
Because the Y1 receptor has a wide range of important phys-
iological functions in addition to its role in the immune sys-
tem (6, 25), it was important to check whether impaired Th1
cell responses in Y1 /  mice were due solely to a defect in
APC function and not to secondary effects resulting from the
lack of the Y1 receptor in the peripheral and central nervous
systems. We used BM chimera animals and transferred Y1 / 
BM into lethally irradiated Y1 /  mice and Y1 /  BM into
Y1 /  mice, creating Y1 /  mice with Y1 /  immune cells
and Y1 /  mice with Y1 /  immune cells, respectively. The
absence of Y1 from immune cells was sufficient to impair
DTH responses (Fig. 7 A), mBSA-specific IgG2a secretion
(Fig. 7 B), and levels of total serum IgG2a (Fig. S1 E). Thus,
the Y1 receptor has an important activating/regulatory role
in the immune system, independent of its functions in other
tissues, such as the central nervous system.
DISCUSSION
Neuroscience and immunology are two areas of research
that historically have evolved separately despite decades of
evidence for bidirectional cross talk. A number of studies
have shown the effects of neurotransmitters and neuropep-
tides on immune cell function in vitro and in vivo (4, 26).
However, very few studies have attempted to pinpoint the
physiological significance of these effects and/or the molecu-
lar basis behind them. Recent studies have established that a
number of factors and receptors, originally described in the
nervous system, are also expressed by immune cells. More-
over, work on the immune system of mice deficient for cer-
tain neuronal molecules has uncovered unexpected roles for
Figure 6. Impaired DC function in Y1 /  mice. (A) OVA-FITC uptake 
by Y1 /  (white bar) and Y1 /  (black bar) immature DCs. Flow cytometry 
was used to quantitated FITC-OVA uptake by DC, and results were plotted 
as mean fluorescence intensity (MFI). Four animals were analyzed per 
group. (B) Representative FACS plot showing OVA-FITC uptake by Y1 /  
(thin line) and Y1 /  (thick line) immature DCs. (C) Both Y1    immature 
DCs (iDC) or DCs stimulated with LPS or anti-CD40 antibody as indicated 
(black bars) have impaired stimulatory functions in MLR compared with 
Y1    cells (white bars). Y1    T cells were used as responders. (D) IL-12p40 
(top) and IL-12p70 (bottom) production by anti-CD40– (left) and LPS-
stimulated (right) Y1 /  (white diamonds) and Y1 /  (black circles) DCs 
measured by ELISA. The results are representative of two separate experi-
ments. White and black squares represent control unstimulated Y1    and 
Y1    cells, respectively. (E) Body weight of RAG1 /  or RAG1 /    Y1 /  
mice days after transfer with Y1 /  CD45RBhi CD4  T cells as indicated. 
Four animals per group. (F) DTH response induced after injection of Y1 /  
mice with mBSA-pulsed Y1 /  (white squares) or Y1 /  (white diamonds) 
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immune function. For instance, semaphorins, originally de-
scribed as guidance molecules for developing neuronal ax-
ons, are now emerging as molecules with powerful effects on
T, B and DC activation and appear necessary for optimal T
cell–APC interactions (27). Interestingly, similar to the Y1
receptor in this study, the expression of the semaphorin
Sema4A on DCs has also been shown to be critical for T cell
priming (24). From this recent work emerged an interesting
parallel between the immunological and neurological syn-
apses and a new basis for immune regulation at the interface
of the nervous and immune systems (27).
Our study highlights the important role of the NPY/Y
receptor system for immune cell function. NPY is produced
by the central and peripheral nervous system as well as by
immune cells in response to activation (8, 22). NPY has a
number of pleiotropic effects in the immune system, ranging
from the modulation of cytokine release to cell migration
and innate immune cell activity (8). Recently, treatment
with NPY has been shown to protect mice against disease in
models of EAE (13) and DTH (unpublished data), suggesting
important functions for NPY receptors as regulators of im-
mune responses in inflammation and autoimmunity. The use
of a Y1 agonist and antagonist suggested that NPY-medi-
ated protection in EAE was triggered via repressive signals
through the Y1 receptor on T cells (13). Although these
results suggest an important role for the NPY–Y1 axis in
the immune system, the true significance of this function
emerged from our study of Y1 /  mice. Indeed, initial ob-
servations were confusing as Y1 /  mice were protected
from colitis and DTH, which appeared to contradict the no-
tion of a protective role for Y1 receptor signaling in inflam-
mation (14). Our study of Y1 /  T cells and Y1 /  APCs
put these observations into a proper perspective and uncov-
ered a sophisticated bimodal role for Y1 in the immune sys-
tem. Isolated Y1 /  T cells are clearly hyperreactive, re-
sponding better in alloreactions and inducing severe colitis
upon transfer into lymphopenic mice. Conversely, the addi-
tion of NPY in a T cell assay suppresses T cell proliferation
in an MLR. We showed that the addition of NPY at the on-
set of T cell activation, but not 24 h after activation, in vitro
was able to trigger this inhibitory effect, suggesting that sig-
naling through Y1 on T cells inhibited T cell activation/ef-
fector differentiation but was not able to shut off the func-
tion of preexisting proliferating effector T cells. In addition,
these results confirmed that Y1 /  T cells are not only capa-
ble of differentiating into active IFN- –producing Th1 T
cells, but are also intrinsically hyperreactive. The results also
confirmed that the Y1 receptor is a key negative regulator
on T cells, controlling the magnitude of T cell responses.
The realization that a problem with Y1 /  T cell function
could not account for the protection seen in Y1 /  mice in
models of DTH and DSS-induced colitis suggested that a
defect in APCs in these mice might explain this protected
phenotype. Indeed, the activation and production of cyto-
kines critical for Th1 cell responses were clearly impaired
in Y1 /  macrophages and in Y1 /  mice, as well as anti-
gen uptake by Y1 /  DCs, which was markedly reduced
and suggested reduced antigen-presenting capacity in Y1 / 
mice. Y1 /  APCs provided reduced proliferative stimuli to
Y1 /  T cells in the MLR, which was consistent with the
reduced number of effector T cells detected in Y1 /  mice.
In addition, our two in vivo systems providing Y1 /  APCs
in the presence of Y1 /  or hyperreactive Y1 /  T cells
confirmed that expression of Y1 on APCs is critical for opti-
mal T cell priming. Therefore, the key immunological pro-
tection in Y1 /  mice derives from a defect in APC func-
tion, which masked the hyperactive nature of the Y1 /  T
cell compartment. Thus, the Y1 receptor fulfils two impor-
tant roles in the immune system: one as an activator of APC
function, and the other as a regulator of T cell responses (see
model in Fig. 7 C).
The powerful effects of Y1 deficiency on both APC and
T cell functions suggest that signaling through Y1 on APCs
and T cells is normally finely balanced to ensure proper im-
mune responses. Our reciprocal BM transfer experiment
Figure 7. BM chimeras revealed an immune-specific role for Y1: a 
proposed NPY/Y1 immune model. (A and B) Y1 /  and Y1 /  mice were 
lethally irradiated and reconstituted with Y1 /  (white circles) and Y1 /  
(white triangles) BM cells, respectively. Y1 /  (white squares) and Y1 /  
(white diamonds) mice are shown as reference. (A) The DTH response to 
mBSA and (B) the mBSA-specific IgG2a response are shown. Six animals 
per group. (C) A proposed model: Upon activation, macrophages secrete 
NPY (reference 13), which through Y1 receptor promotes the secretion of 
TNF and IL-12 important for T cell differentiation into Th1 effector cells. Y1 
expression on DCs is important for optimal antigen uptake and presenta-
tion to T cells. In contrast, signaling through Y1 receptor on T cells inhibits 
T cell activation. p-values as in Fig. 1.JEM VOL. 202, December 5, 2005 1535
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clearly showed that when endogenous expression of NPY is
physiological, the function of Y1 in the immune system is
independent of its function in the central and peripheral ner-
vous systems. However, excessive and/or chronic systemic
release of NPY as a result, for example, of psychological
stress or depression (28) would strongly inhibit T cell activa-
tion and predictably increase the vulnerability of the stressed
individual to infections and cancer (1) or other forms of im-
mune dysfunction. Interestingly, a recent report showed that
Y1 receptor expression is reduced in T cells from schizo-
phrenic patients (29). Immune defects and in particular de-
fects in Th1 T cell responses are well documented in schizo-
phrenic patients (30). Schizophrenic patients share a few
common features with Y1 /  mice, such as a greater pro-
portion of circulating naive T cells (31), increased in vitro T
cell responses, but reduced T cell activation to tuberculin in
vivo (32). It will therefore be interesting to examine the ex-
pression of Y1 on APCs from schizophrenic patients.
Currently, the natural advantages of the bimodal mecha-
nism of immune cell regulation through Y1 are not entirely
clear, and it will be important to integrate this effect within a
general schema of immune regulation by neurotransmitters
(1). Most likely, the inhibition of T cell activation by excess
NPY is a physiological counterbalance that prevents adverse
concurrent effects from APCs overstimulated by NPY,
which might otherwise corrupt T cell tolerance (33). In-
deed, the treatment of macrophages with NPY elevates cy-
tokine production and inflammatory responses in vitro (34);
therefore, elevated serum NPY levels in response to psycho-
logical stress (in addition to NPY produced locally by
immune cells) would likely trigger inappropriate APC acti-
vation and inflammation if a concomitant antagonistic activ-
ity of NPY in T cells was not in place. However, as NPY
can trigger proinflammatory effects in macrophages, we can-
not exclude lymphocyte-independent inflammatory disorders
triggered by excess production of NPY. This may explain
why Y1 antagonists provide an effective protection against
DSS-induced colitis. This model of colitis is highly depen-
dent on the activation of macrophages (18) and can be trig-
gered in lymphopenic mice (35). Therefore, blocking Y1 on
macrophages was a key event in protecting mice against
DSS-induced colitis. This is in contrast to DTH, a model
highly dependent on T cell activation (36), and therefore,
protection in this model relied strongly on agonist signals
through Y1 on T cells. A number of inflammatory condi-
tions, such as asthma, correlate with elevated serum levels of
NPY, and production was not explained by the increased
formation of NPY-producing nerve terminations in in-
flamed tissues (25). This suggests that immune cells rather
than nerves might be the source of additional NPY (22, 34).
It is possible that the immune system adopted the Y1/NPY
receptor–ligand system for immune cell regulation and that
central nervous system–derived NPY has inadvertent effects
on immune function. Another possibility is that central ner-
vous system peptides, produced as a result of stress, etc., play
a meaningful role in modulating immune cell function for
unknown reasons. Regardless, increased production of NPY
in response to psychological stress does modulate immune
responses (1), and it will be important to understand the cir-
cumstances of NPY production by both neurones and im-
mune cells, and how increased NPY production by activated
immune cells during inflammation may affect other NPY-
mediated physiological and psychological functions.
In conclusion, this work uncovers a powerful new
mechanism for Y1 neuropeptide receptor in regulating both
APC and T cell functions. This bimodal role for Y1 receptor
likely represents an important interface between the periph-
eral nervous system and the immune system. Understanding
signaling events through the Y1 receptor on immune cells
may disclose novel strategies for immunomodulation and
improve our understanding of the effect of psychological
stress on immune functions.
MATERIALS AND METHODS
Mice. Mice lacking the Y1 receptor (Y1 / ) have been described (37).
8–12-wk-old male and female mice were used for the studies. 12–14-wk-
old RAG1 /  and BALB/c mice were obtained from Animal Resources Cen-
ter. Homozygote Y1 /  and RAG /  mice were crossed, and seven pairs of
these double heterozygote mice were used to generate double Y1 /   
RAG /  KO and control mice. From the generated 110 offspring of these
breeding pairs, four double KO mice were identified, slightly less than the
expected seven according to Mendelian rules. Animals were housed under
conventional barrier protection and handled in accordance with the Animal
Experimental and Ethic Committee, which complies with the Australian
code of practice for the care and use of animals for scientific purposes. The
response of these mice to T-dependent and -independent antigens was con-
ducted as described previously (38).
Flow cytometry. T and B lymphocyte subsets from the LNs, spleen,
peritoneal lavage, BM, and thymus were isolated and analyzed by four-
color flow cytometry as described previously (15, 39). Lymphocytes from
the LNs, spleen, BM, and thymus were isolated by mechanical disruption of
the organs followed by a 5-min incubation in RBC lysis buffer (0.156 M
ammonium chloride, 0.01 M sodium bicarbonate, and 1 mM EDTA) on
ice. For multicolor flow cytometric analysis, cells were incubated in the
presence of fluorochrome- and biotin-conjugated mAbs against CD21/
CD35 (7G6), CD23 (B3B4), B220 (RA3-6B2), CD43 (1B11), CD4
(L3T4), CD8 (53–6.7), CD44 (IM7), L-selectin (MEL-14), CD5 (Ly-1),
IgD (11-26c.2a), IgM (R6-60.2), CD25 (PC61), CD69 (H1.2F3),
CD45RB (16A), CD11b (M1/70), CD11c (HL3), MHC class II (I-A/I-E,
2G9), CD80 (16-10A1), CD86 (B7-2), and CD40 (3/23; BD Biosciences).
When biotinylated antibodies were used, strepatvidin-PerCP (BD Bio-
sciences) or streptavidin-Cy5 (Jackson ImmunoResearch Laboratories) al-
lowed detection. For labeling with CFSE (Invitrogen), T cells at a density
of 107 cells/ml were incubated for 10 min at room temperature in 5  M
CFSE in PBS containing 0.1% BSA. The labeling reaction was stopped by
the addition of serum. Cells were analyzed by FACS analysis. Reduction in
CFSE mean of fluorescence is indicative of cell division.
ELISA. For detection of serum Ig, plates were coated with 2  g/ml goat
anti–mouse Ig (H L; Southern Biotechnology Associates, Inc.) at 4 C
overnight. Plates were then blocked with 3% skim milk powder for 1 h at
37 C. Serum serial dilutions were incubated for 1 h at 37 C with serial dilu-
tions of serum. Alkaline phosphatase–labeled goat anti–mouse IgG1, IgG2a,
IgG2b, IgG3, IgA, or IgM (Southern Biotechnology Associates, Inc.) were
used as secondary antibodies, diluted at 1:2,000, and incubated at 37 C forTHE IMMUNOLOGICAL ROLE OF NEUROPEPTIDE Y1 RECEPTOR | Wheway et al. 1536
1 h. The reaction was developed using p-NP phosphate in 10% diethanola-
mine (Sigma-Aldrich) and stopped with 3 M NaOH. The optical density
was measured at 405 nm. The detection of T-dependent and -independent
NP-specific antibodies was performed as described previously (38). Anti-
mBSA–specific antibodies were captured by coating the ELISA plate with
10  g/ml mBSA (Sigma-Aldrich) and detected as described above. The ti-
ter (log base 2) for anti-NP antibodies was defined as the serum dilution
giving an OD four times higher than that of the background (1   1/100 di-
lution). Cytokine ELISAs for TNF, IL-12p40, IL-12p70, IL-4, and IFN- 
were performed using kits purchased from BD Biosciences, and the IL-2
cytokine ELISA was performed using a kit supplied by PeproTech. All kits
were used according to the manufacturers’ specifications.
Preparation and stimulation of BM-derived DCs. BM was flushed
with a syringe from the tibias and femurs of Y1 /  and Y1 /  mice, and
red cells were lysed. The remaining cells were depleted of erythroid precur-
sors and granulocytes as well as T, B, and NK cells using magnetic cell sort-
ing according to the manufacturer’s instructions (MACS; Miltenyi Biotec).
After depletion, 2   105 cells were seeded in nontreated 10-cm dishes, cul-
tured in RPMI plus 10% fetal bovine serum, 2% penicillin/streptomycin,
and 1% of 200 mM glutamine containing 20 ng/ml GM-CSF and 20 ng/ml
IL-4, and incubated at 37 C/5% CO2. Medium was replenished on days 3,
5, and 7. At day 8, nonadherent cells were collected and adherent cells were
discarded. These cells were immature DCs, and purity was confirmed by
FACS analysis using anti-CD11c mAb (BD Biosciences). Mature DCs were
obtained after stimulation with either 1 mg/ml LPS or 10  g/ml anti-
CD40 (BD Biosciences) for 24 h. The ability of immature DCs to take up
fluorescently labeled protein was assessed using FACS analysis after the cells
were incubated with 1 mg/ml FITC-OVA or FITC-dextran (Invitrogen) at
37 C for 30 min and washed three times with PBS. For MLR, immature
and mature DCs were inactivated by   irradiation, washed, and mixed with
CD3  BALB/c-derived splenocytes. The optimal ratio of DCs to T cells
was determined to be 1:10. Proliferation after 3 d was measured by pulsing
cells with 1  Ci/well [3H]thymidine for the final 18 h of stimulation.
Preparation and stimulation of thioglycollate-elicited macrophages.
Y1 /  and Y1 /  mice were injected i.p. with 2 ml 3% thioglycollate (Sigma-
Aldrich) 3 d before they were killed. Peritoneal macrophages were collected
by peritoneal lavage with 5 ml of sterile RPMI 1640 medium. Macrophages
were purified by adherence to tissue culture plates for 2 h. The macrophage
population was  92–95% Mac-1  (CD11b antibody; BD Biosciences) by
FACS analysis. Peritoneal macrophages plated at 2   106 cells/ml were treated
with 100 ng/ml of LPS (Sigma-Aldrich) or 1  g/ml R848 (Invivogen) or 10
 g/ml PGN (Invivogen) for 4 h. The Y1-specific antagonist peptide GW1229
was designed as described previously (40) and custom made by AUSPEP. The
antagonist Y1-specific peptide was used at 10 8 M in culture.
DTH model. mBSA-induced DTH was performed as described previ-
ously (41). In brief, mice were sensitized with 1.25 mg/ml mBSA (Sigma-
Aldrich) in CFA, injected subcutaneously at the base of the tail. 7 d after the
sensitization, mice were challenged with 200  g/20  l mBSA in the right
footpad and 20  l PBS was injected into the left footpad. Footpad swelling
was measured using a calliper and calculated as follows: (footpad swelling
[%])   [(thickness of mBSA-injected footpad) [mm])   (thickness of PBS-
injected footpad [mm])] / (thickness of PBS-injected footpad [mm])   100.
For the DC-induced DTH responses (adapted from references 23 and 24),
day 8 immature BM-derived immature DCs (prepared as described above)
were pulsed with 50  g/ml mBSA plus 0.2  g/ml anti-CD40 in X-Vivo
15 serum-free media (Cambrex) for 24 h. 106 pulsed DCs were injected
subcutaneously at the base of the tail. 7 d after the sensitization, mice were
challenged with 600  g mBSA in 30  l PBS in the right footpad. 30  l
PBS was injected into the left footpad for control. Footpad swelling was
measured and calculated as described above.
T cell stimulation assays. For recall responses, lymphocytes were iso-
lated from inguinal LNs from mice 14 d after the initial tail-base injection of
mBSA. T cell numbers were normalized and cells were plated at 2   105 T
cells/well. Cells were stimulated with 4  g/ml mBSA for 72 h and superna-
tant was collected for ELISA. For measurement of cell proliferation, cells
were pulsed with 1  Ci/well [3H]thymidine for 18 h before harvest. Stim-
ulation index equals the counts from activated cells/counts from nonstimu-
lated cells. T cells were isolated from Y1 /  and Y1 /  mice using a MACS
Pan T cell negative selection kit (Miltenyi Biotec) according to the manu-
facturer’s specifications. 95% purity was confirmed by FACS analysis. In
vitro T cell stimulations (with anti-CD3 /  anti-CD28 antibodies; BD
Biosciences) were performed as described previously (42). For MLR, using
BALB/c-derived splenocytes for MHC mismatch, stimulator cells were first
inactivated for 20 min with 200  g/ml mitomycin C (Sigma-Aldrich),
washed, and mixed at a ratio of 1:1 with CD3  responder cells. Prolifera-
tion after 6 d was measured by pulsing cells with 1  Ci/well [3H]thymidine
for the final 18 h of stimulation.
Models of colitis. Acute colitis was induced by administering 3.5% (wt/
vol) DSS (mol wt: 36,000–50,000; ICN Biochemicals Inc.) for 7 d in males
and 8 d in females ad libitum. Mice were weighed every day and per-
cent weight change for each mouse was calculated as follows: % weight
change   (weight at specific day   weight on day 0) / weight on day 0)  
100. The CD4  CD45RBhi transfer model of colitis was induced in Y1 / 
RAG1 /  and Y1 /  RAG1 /  mice by injecting i.v. 2   105 sorted
CD4  CD45RBhi cells purified as described previously (21) from either
Y1 /  or Y1 /  mice. Animal body weight was monitored weekly for 2
wk and then daily. Upon loss of 20% original body weight, mice were
culled for organ collection. Weight loss appeared simultaneously with diar-
rhea. % weight change   (weight at specific day   weight on day 0) /
weight on day 0)   100.
Immunohistochemistry. Colons were collected from mice undergoing
colitis models and frozen in OCT compound (Tissue-Tek; Sakura). 7- m-
thick tissue sections were stained with hematoxylin and eosin for histologic
examination as described previously (43).
Quantitative PCR. Total RNA was isolated from cells or tissue using
TRIzol reagent (Invitrogen). After cDNA synthesis using the Reverse-IT
RTase Blend Kit (ABgene), real-time PCR was conducted using the Light
Cycler-FastStart DNA Master SYBR Green I Kit (Roche Molecular Bio-
chemicals) according to the manufacturer’s specifications. The following
primers were used: mY1 forward: 5 -CAAATTCTGACCGACGAGCC-
3 , reverse: 5 -TAAAGCAGAGTGGGCCGAAA-3 ; and mGAPDH for-
ward: 5 -CTCATGACCACAGTCCATGC-3 , reverse: 5 -CACATTG-
GGGGTAGGAACAC-3 .
Whole spleen and thymus homogenized for total RNA preparation.
B220 /CD3  (B cells), CD4  and CD8  T cells, NK1.1  CD3  NK cells,
and CD11c  DCs were sorted using a FACSVantage SE DiVa (Becton
Dickinson). All antibodies were purchased from BD Biosciences. Macro-
phages were thioglycollate-elicited and lymphocyte-depleted as described
above. Sorted cell preparations were always  95% purity. Mouse mast cells
(prepared as described elsewhere; reference 44) and mouse DCs (see proto-
col above) were BM cell–derived and had a purity of between 90 and 95%.
BM chimeras. 8–10-wk-old recipient mice were lethally irradiated (950
rad) and rescued 6–8 h later with an i.v. injection of 2   107 BM cells. Chi-
meras were analyzed 6–8 wk after reconstitution.
Online supplemental material. Fig. S1 shows that T cells from Y1 / 
mice responded with much higher proliferation to suboptimal doses of anti-
CD3 than did WT T cells (Fig. S1, A). This was also confirmed by CFSE
staining in Y1 /  and Y1 /  T cells after activation with anti-CD3 (Fig. S1JEM VOL. 202, December 5, 2005 1537
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B). However, this increased capacity for proliferation did not extend to IL-2
production as T cells from Y1 /  and Y1 /  mice showed equivalent IL-2
production after stimulation (Fig. S1 C). In addition, expression of the acti-
vation marker CD69 72 h after activation with anti-CD3 or anti-CD3 plus
anti-CD28 was equivalent in Y1 /  and Y1 /  T cells (Fig. S1 D). Lastly,
total IgG2a was measured in Y1 /  and Y1 /  mice lethally irradiated and
reconstituted with Y1 /  or Y1 /  BM cells. This established that effects of
Y1 on IgG2a production could be attributed to transferred BM-derived
cells.
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